Martin Cowie, of AstraZeneca, Discusses the ESC 2023 Heart Failure Guidelines Update

The European Society of Cardiology (ESC) Task Force recently completed a Focused Update of their 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure (HF). Notably, SGLT2 inhibitors received a Class I recommendation for HF with a mildly reduced and preserved ejection fraction.

In this interview, DocWire News spoke with Martin Cowie, clinical vice president, cardiovascular and heart failure, biopharmaceuticals R&D at AstraZeneca, who reviewed the ESC’s updated guidelines and discussed the SGLT2 inhibitor Farxiga, one of the HF therapies with a Class 1A recommendation.

Mr. Cowie also detailed 2 trials that played a central role in these guideline updates, the DAPA-HF and DELIVER trials.